Patents Assigned to Merck
  • Liquid-crystalline compounds
    Publication number: 20030213935
    Abstract: Liquid-crystalline compounds of the formula I 1
    Type: Application
    Filed: September 30, 2002
    Publication date: November 20, 2003
    Applicant: Merck Patent GmbH
    Inventors: Michael Heckmeier, Peer Kirsch, Joachim Krause, Alexander Hahn, Andreas Ruhl
  • Infrared-reflective material
    Publication number: 20030215627
    Abstract: The invention relates to an infrared-reflective material which comprises a transparent sheet material which comprises, on a part-area, an interference pigment which has higher transmission in the visible region of global radiation than in the NIR region, to a method for screening an enclosed area against infrared light, and to the use of the infrared-reflective material for buildings, vehicles and greenhouses while simultaneously maintaining the ability of the human eye to see through the material.
    Type: Application
    Filed: May 14, 2003
    Publication date: November 20, 2003
    Applicant: Merck Patent GmbH
    Inventors: Silvia Rosenberger, Guido Olbers, Dieter Heinz
  • Apparatus and method for sharing session information
    Publication number: 20030217159
    Abstract: A system and method are disclosed for sharing session information. The system comprises a database system, a first computer system capable of accessing the database system, and a second computer system also capable of accessing the database system. A user accesses a first website hosted by the first computer system, and a session is initialized for the user. A profile object is created for the user and serialized. The serialized profile object is subsequently stored in the database system with a key. The second computer system queries the database system in order to retrieve the serialized profile object matching the key. The second computer deserializes the profile object and restores the session at the second website together with shared session information.
    Type: Application
    Filed: March 18, 2003
    Publication date: November 20, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Susan Schramm-Apple, Sean Dippold, Melanie Kittrell, Keith Bauer, Lori Moore
  • Gene therapy for obesity
    Publication number: 20030215423
    Abstract: Gene therapy can treat obesity in mammals. An obesity regulating gene is delivered to a mammal. Preferably, the gene encodes leptin or a leptin receptor. The protein which is delivered and expressed in vivo is more effective than protein which is injected into the animal.
    Type: Application
    Filed: April 21, 2003
    Publication date: November 20, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Manal A. Morsy, Ming Cheng Gu, Jing Zhoa, C. Thomas Caskey, Stephan Kochanek
  • Protein tyrosine phosphate-1B (PTP-1B) deficient mice and uses thereof
    Publication number: 20030217379
    Abstract: The present invention provides mice that have had their PTP-1B genes disrupted by targeted homologous recombination. The mice have no detectable PTP-1B protein, yet appear to be physiologically normal. However, in the fed state on a normal diet, the mice have half the level of circulating insulin as their wild-type littermates. In glucose and insulin tolerance tests, the mice show an increased insulin sensitivity. When fed a high fat, high carbohydrate diet, the mice show a resistance to weight gain as compared to their wild-type littermates. Methods of making the mice and cell lines derived from the mice are also provided. The present invention also provides methods of idendifying inhibitors of the enzymatic activity of PTP-1B as well as inhibitors identified by such methods.
    Type: Application
    Filed: June 12, 2003
    Publication date: November 20, 2003
    Applicants: Merck & Co., Inc., McGill University
    Inventors: Brian Kennedy, Paul Payette, Michael Gresser, Chidambaram Ramachandran, Michel Trembly, Mounib Elchebly
  • Methods and compositions of treating and/or preventing diabetic retinopathy with pericyte apoptosis inhibitors
    Publication number: 20030216290
    Abstract: A method of preventing or treating diabetic retinopathy is disclosed including administering to a mammal a therapeutically effective amount of an inhibitor of retinal pericyte apoptosis. Also disclosed is a pharmaceutical composition which treats and/or prevents diabetic retinopathy comprising as an active agent a therapeutically effective amount of at least one inhibitor of retinal pericyte apoptosis and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 23, 2003
    Publication date: November 20, 2003
    Applicants: Merck Sante, a corporation of France, INSERM, a corporation of France
    Inventors: Marc Lecomte, Ulriche Denis, Clarisse Paget, Nicolas Wiernsperger, Michel Lagarde
  • Oxabicyclooctanes
    Publication number: 20030215580
    Abstract: The present invention relates to oxabicyclooctanes of the general formula I.
    Type: Application
    Filed: October 1, 2002
    Publication date: November 20, 2003
    Applicant: Merck Patent GmbH
    Inventors: Matthias Bremer, Michael Heckmeier, Melanie Klasen-Memmer, Harald Lannert
  • Liquid-crystal medium, and electro-optical liquid-crystal display
    Patent number: 6649228
    Abstract: The present invention relates to liquid-crystalline media which comprise at least one compound of the formula I and at least one compound of the formula II in which the parameters are as defined herein, to the use of these liquid-crystal media in electro-optical displays, and to these displays, in particular STN-LCDs.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: November 18, 2003
    Assignee: Merck Patent Gesellschaft mit Beschraenkter Haftung
    Inventors: Juliane Suermann, Bernhard Rieger
  • Multilayer nacreous pigment
    Patent number: 6648957
    Abstract: Multilayer pearl lustre pigment on the basis of a platelet-shaped substrate comprising a material of low refractive index in the range from 1.35 to 1.8, which comprises at least (i) one first layer comprising a material having a refractive index of more than 1.8, (ii) optionally, a second layer comprising a material of low refractive index in the range from 1.35 to 1.8, (iii) a semitransparent metal layer which is applied to the substrate or to the layers (i) or (ii), and (iv) if desired, an aftercoating, the substrate being platelet-shaped silicon dioxide, aluminium oxide, boron oxide or magnesium fluoride.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: November 18, 2003
    Assignee: Merck Patent GmbH
    Inventors: Stephanie Andes, Gerald Fuchs-Pohl, Gerhard Pfaff
  • Nematic liquid crystal mixtures and a matrix liquid crystal display
    Patent number: 6649088
    Abstract: A nematic liquid crystal mixture having a positive dielectric anisotropy &Dgr;∈ of at least +4 and a birefringence &Dgr;n of at least 0.12, characterized in that the mixtures comprises one or more components having the core structure wherein L1, L2, Y and Z are each independently of one another H or F, one of Q1 and Q2 is 1,4-phenylene, 3-fluoro-1,4-phenylene or 3,5-difluoro-1,4-phenylene and the other residue Q1 or Q2 is —CH2CH2—, —CH2CH2CH2CH2— or—if at least one of L1, L2, Y and Z denotes F—also a single bond, whereby this core structure can be optionally further fluorinated in the benzene rings.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: November 18, 2003
    Assignee: Merck Patent GmbH
    Inventors: Bernhard Rieger, Volker Reiffenrath, Reinhard Hittich
  • Highly light-scattering pigment mixture
    Patent number: 6648958
    Abstract: Highly light-scattering pigment mixture featuring (i) 70-99.9% by weight of a component A consisting of spherical silicon dioxide with a diameter of less than 50 &mgr;m, coated with titanium dioxide and optionally a further layer of SiO2, and (ii) 0.1-30% by weight of a component B consisting of spherical silicon dioxide with a diameter of less than 50 &mgr;m, coated with titanium dioxide as a first layer and iron(III) oxide as a second, outer layer, the refractive index of the pigment being adjusted to a value of between 1.45 and 1.65.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: November 18, 2003
    Assignee: Merck Patent Gesellschaft
    Inventors: Ralf Anselmann, Martin Knapp, Uta Hillgärtner
  • STN liquid crystal display
    Patent number: 6649229
    Abstract: The invention relates to supertwist liquid-crystal displays (SLCDs) having very short response times and good steepnesses and angular dependences and to the novel nematic liquid-crystal mixtures employed therein, which are distinguished by the fact that they comprise at least one compound of the formula, IA and at least one compound of the formula IB and/or at least one compound of the formula IC in which Ra, Rb, Rc, Rd, Re, Y1, Y2, Y3, Y4, q and p are as defined herein.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: November 18, 2003
    Assignee: Merck Patent GmbH
    Inventor: Harald Hirschmann
  • Diacylhydrazine derivatives
    Patent number: 6649613
    Abstract: Diacylhydrazine derivatives of general formula (I) wherein X, Y, Z, R1, 2 and R3 are as defined herein, and their physiologically acceptable salts or solvates thereof, are integrin inhibitors and can be used to combat thromboses, myocardial infarcts, coronary cardiac diseases, arteriosclerosis, inflammations, tumors, osteoporosis, infections, and restenosis following angioplasty or during pathological processes that are maintained or propagated by angiogenesis.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: November 18, 2003
    Assignee: Merck Patent GmbH
    Inventors: Günter Hölzemann, Simon Goodman, Horst Kessler, Christoph Gibson, Gabór Sulyok
  • Method for producing mannitol
    Patent number: 6649754
    Abstract: A process for preparing mannitol from fructose is described and entails the hydrogenation of fructose taking place in the presence of a Raney copper catalyst and being carried out continuously.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: November 18, 2003
    Assignee: Merck Patent GmbH
    Inventors: Thomas Mohr, Eugen Schwarz, Peter-Johannes Mackert
  • Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent for treatment of depression or anxiety
    Patent number: 6649614
    Abstract: The present invention relates to the treatment of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: November 18, 2003
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Emma Joanne Carlson, Nadia Melanie Rupniak
  • Process for preparing piperazinepentaneamide HIV protease inhibitors
    Patent number: 6649761
    Abstract: A process for preparing &ggr;-hydroxy-4-[[2-oxazolyl]alkyl]-&agr;-[(cyclo)alkyl- or aryl- or heteroaryl-substituted methyl]-2-[[(un)substituted alkyl]aminocarbonyl]-1-piperazinepentanamides is disclosed. The piperazinepentanamides are useful as HIV protease inhibitors. A process for making a 4-[[2-oxazolyl]alkyl]-2-[[(un)substituted alkyl]aminocarbonyl]piperazine by treating a ketoamide precursor with fuming sulfuric acid in the presence of polyphosphoric acid is also disclosed. In addition, a process for enhancing the optical purity of 4-[[2-oxazolyl]alkyl]-2-[[(un)substituted alkyl]aminocarbonyl]-piperazines via the formation 2-naphthalenesulfonic acid crystal salts thereof is disclosed, as well as a method for purifying 2-naphthalenesulfonic acid.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: November 18, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Norihiro Ikemoto, Jinchu Liu
  • Pigment preparation
    Patent number: 6648956
    Abstract: The invention relates to a nondusting, solvent-containing homogeneous pigment preparation that includes ≧70% by weight of one or more effect pigments 0.1-30% by weight of an organic solvent or solvent mixture having an evaporation number (EN) of 10 to 100 and a surface tension (ST) of ≦35 mN/m and optionally 0-5% by weight of a surface-active substance.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: November 18, 2003
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Wolfgang Hechler, Gerhard Herget, Brigitte Husseini, Sabine Schoen
  • Method of treating colonic adenomas
    Patent number: 6649649
    Abstract: This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: November 18, 2003
    Assignees: Merck & Co., Inc., Merck Frosst Canada, & Co.
    Inventors: Stacia Kargman, Thomas J. Simon, Jilly Evans
  • Immediate release tablet containing naproxen sodium
    Publication number: 20030211150
    Abstract: The present invention relates to a new tablet having an improved dissolution rate of Naproxen Sodium comprising Naproxen Sodium and spray-dried mannitol. The invention further relates to a method of manufacturing said tablet.
    Type: Application
    Filed: November 21, 2002
    Publication date: November 13, 2003
    Applicant: Merck Patent GmbH
    Inventors: Ahmad Al-Ghazawi, Kalyan S. Nuguru, Dan F. Giambattisto
  • Dihydroxy open-acid and salts of HMG-Co-A reductase inhibitors
    Publication number: 20030211151
    Abstract: The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.
    Type: Application
    Filed: April 29, 2003
    Publication date: November 13, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Richard D. Tillyer, Paul J. Reider, Edward J. J. Grabowski, Feng Xu, Jose M. Vega, Mandana Asgharnejad